PUMA BIOTECHNOLOGY, INC. Receivables, Net, Current
PUMA BIOTECHNOLOGY, INC. (PBYI) had Receivables, Net, Current of $1.18 million as of 2016-09-30, per its 10-Q filed 2016-11-09.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:ReceivablesNetCurrent · last filed 2016-11-09
- 2016-09-30: Receivables, Net, Current $1.18M.
- 2016-06-30: Receivables, Net, Current $1.18M.
| Period end | Receivables, Net, Current |
|---|---|
| 2016-09-30 | $1.18M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $1.18M 10-Q · filed 2016-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |